Yttrium-90 radioembolization stops progression of targeted breast cancer liver metastases after failed chemotherapy.

ABSTRACT:

Purpose

To determine, in an open-label, retrospective report, the safety and effectiveness of locoregional therapy with yttrium-90 ((90)Y) radioembolization for patients with progressing breast cancer liver metastases (BCLMs) despite multi-agent chemotherapy.

Materials and methods

Seventy-five patients with progressing BCLMs and stable extrahepatic disease were treated with radioembolization at a single institution. Retrospective review of a prospectively collected database was performed to evaluate clinical and biochemical toxicities, tumor response, overall survival (OS), and time to progression. Radiologic response assessments included Response Evaluation Criteria In Solid Tumors in primary index lesions and metabolic activity on positron emission tomography (PET). Univar

SUBMITTER: Gordon AC 

PROVIDER: S-EPMC4720166 | biostudies-literature | 2014 Oct

REPOSITORIES: biostudies-literature